Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
Clinical role
Concurrent reading aid for physicians interpreting screening FFDM and DBT exams that outputs locations of calcification groups and soft-tissue regions with cancer-likelihood scores, plus an exam score; patient management decisions should not be made solely on its analysis.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Adjunctive concurrent aid only; patient-management decisions must not rely solely on the device; intended population is women undergoing screening mammography/DBT.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible screening full-field digital mammography and digital breast tomosynthesis exams in DICOM.
Who uses it?Intended users: Physicians qualified to read screening mammography and digital breast tomosynthesis exams.
What does the software produce?Output: CAD marks for suspicious calcifications or soft-tissue lesions, 0-100 region scores, corresponding-region links, and a 1-10 exam score.
What is its most important limitation?Key limitation: Adjunctive concurrent aid only; patient-management decisions must not rely solely on the device; intended population is women undergoing screening mammography/DBT.
Clinical takeaway. Clinical role: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
Evidence takeaway. Evidence from the reviewed source record: FDA reports 10,690 exams: FFDM sensitivity 95.0% (93.5-96.4) at 0.30 FP/image, DBT sensitivity 93.2% (91.0-95.1) at 0.34 FP/volume, and AUC 0.945 for each; specificity is not reported.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Concurrent reading aid for physicians interpreting screening FFDM and DBT exams that outputs locations of calcification groups and soft-tissue regions with cancer-likelihood scores, plus an exam score; patient management decisions should not be made solely on its analysis.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Transpara® software is intended for use as a concurrent reading aid for physicians interpreting screening full-field digital mammography exams and digital breast tomosynthesis exams from compatible FFDM and DBT systems" … "Output of the device includes locations of calcifications groups and soft-tissue regions, with scores indicating the likelihood that cancer is present, and an exam score". Read from the exact FDA decision document on 2026-11-14.
For use in a healthcare facility or hospital, in women undergoing screening mammography and digital breast tomosynthesis.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Transpara® is a software medical device for use in a healthcare facility or hospital with the following indications for use:" … "The device is intended to be used in the population of women undergoing screening mammography and digital breast tomosynthesis.". Read from the exact FDA decision document on 2026-11-14.
Adjunctive concurrent aid only; patient-management decisions must not rely solely on the device; intended population is women undergoing screening mammography/DBT.
FDA reports 10,690 exams: FFDM sensitivity 95.0% (93.5-96.4) at 0.30 FP/image, DBT sensitivity 93.2% (91.0-95.1) at 0.34 FP/volume, and AUC 0.945 for each; specificity is not reported.
Exact FDA submission
Checked 2026-09-19
Submission-reported FDA standalone evidence summary.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reports 10,690 exams: FFDM sensitivity 95.0% (93.5-96.4) at 0.30 FP/image, DBT sensitivity 93.2% (91.0-95.1) at 0.34 FP/volume, and AUC 0.945 for each; specificity is not reported.
FDA source
Exact FDA submission
Checked 2026-09-19
Submission-reported FDA standalone evidence summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Transpara 1.7.2 regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K221347
Samplen=10690
Sites7
IndependenceIndependence not established
K221347
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K221347. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Compatible screening full-field digital mammography and digital breast tomosynthesis exams in DICOM.
Scope: Exact FDA submission. FDA input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Transpara accepting mammograms or DBT exams in DICOM format and sending its output via the DICOM protocol to destinations, commonly medical workstations, PACS and RIS. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Results of Transpara® are computed in processing server which accepts mammograms or DBT exams in DICOM format as input, processes them, and sends the processing output to a destination using the DICOM protocol." … "Common destinations are medical workstations, PACS and RIS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Transpara as computing results in a processing server configured through a service interface, with the end-user interface in a medical workstation provided by third parties. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Results of Transpara® are computed in processing server which accepts mammograms or DBT exams in DICOM format as input, processes them, and sends the processing output to a destination using the DICOM protocol." … "The system can be configured using a service interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: CAD marks for suspicious calcifications or soft-tissue lesions, 0-100 region scores, corresponding-region links, and a 1-10 exam score.
Scope: Exact FDA submission. FDA output description.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: CAD marks for suspicious calcifications or soft-tissue lesions, 0-100 region scores, corresponding-region links, and a 1-10 exam score.
Scope: Exact FDA submission. FDA output description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Transpara as computing results in a processing server configured through a service interface, with the end-user interface in a medical workstation provided by third parties. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Results of Transpara® are computed in processing server which accepts mammograms or DBT exams in DICOM format as input, processes them, and sends the processing output to a destination using the DICOM protocol." … "The system can be configured using a service interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes Transpara accepting mammograms or DBT exams in DICOM format and sending its output via the DICOM protocol to destinations, commonly medical workstations, PACS and RIS. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Results of Transpara® are computed in processing server which accepts mammograms or DBT exams in DICOM format as input, processes them, and sends the processing output to a destination using the DICOM protocol." … "Common destinations are medical workstations, PACS and RIS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Transpara 1.7.2; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.
Transpara 1.7.2 · K221347. Name for this exact FDA record, not an alias for every commercial configuration. Name source
Transpara 2.1.0 · K241831. Name for this exact FDA record, not an alias for every commercial configuration. Name source
Transpara reading aid
Concurrent screening mammography and DBT reading aid. Applies to K221347, K241831. This describes the mapped function only; feature parity and a shared license are not established.
K241831 · 2024-11-25. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K221347 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.